Researchers conducted a systematic review and meta-analysis to evaluate how well a specific drug combination works for younger patients with acute myeloid leukemia (AML). They looked at data from 429 patients with an average age of 54 years across eight different studies. The treatment combined hypomethylating agents (HMA) with a drug called venetoclax.
The analysis found that about 66% of patients achieved complete remission or remission with incomplete blood count recovery. About 69% achieved measurable residual disease negativity, meaning no detectable cancer cells remained. Approximately 75% of patients were alive after one year, and 66% were able to proceed to stem cell transplant.
This review combined results from different types of studies, including two randomized trials, two phase 2 trials, and four real-world studies. Because it wasn't a single controlled trial comparing this approach directly to standard treatments, the findings should be seen as promising but preliminary. The researchers note these results provide a good reason to conduct more rigorous, prospective randomized trials to compare this drug combination against standard intensive chemotherapy regimens.
